GlobeNewswire Inc.··Askbio Inc.Bayer-Owned AskBio Completes Phase 2 Trial Enrollment for Heart Failure Gene Therapy
AskBio completes enrollment of 173 patients in Phase 2 trial for AB-1002 gene therapy targeting heart failure. Results expected H1 2027.
BAYRYclinical trialheart failure